海军军医大学第二附属医院(长征医院)的研究
选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。
只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出
- 食管鳞状细胞癌Oesophageal squamous cell carcinoma3 篇牵头论文
- 肝细胞癌Hepatocellular carcinoma15 篇牵头论文牵头 1 项开放试验
- 胃癌Stomach cancer17 篇牵头论文牵头 1 项开放试验
- 脊索瘤Chordoma5 篇牵头论文
- 骨肉瘤Osteosarcoma16 篇牵头论文
- 胃肠道间质瘤Gastrointestinal stromal tumour4 篇牵头论文
- 神经母细胞瘤Neuroblastoma0 篇牵头论文
- 尤文肉瘤Ewing sarcoma2 篇牵头论文
- 多发性骨髓瘤Multiple myeloma26 篇牵头论文牵头 2 项开放试验
- 血栓性血小板减少性紫癜Thrombotic thrombocytopenic purpura1 篇牵头论文
- 抗 NMDA 受体脑炎Anti-NMDA receptor encephalitis1 篇牵头论文
- 特发性肺纤维化Idiopathic pulmonary fibrosis2 篇牵头论文
- 肌萎缩侧索硬化症Amyotrophic lateral sclerosis0 篇牵头论文
- 白塞病Behçet disease1 篇牵头论文
- IgA 肾病IgA nephropathy5 篇牵头论文
- 成骨不全症Osteogenesis imperfecta2 篇牵头论文
- 原发性胆汁性胆管炎Primary biliary cholangitis1 篇牵头论文
- 家族性腺瘤性息肉病Familial adenomatous polyposis1 篇牵头论文
未列出的收录疾病:鼻咽癌、肝母细胞瘤、视网膜母细胞瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、大动脉炎、肝包虫病、肺淋巴管平滑肌瘤病、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、戈谢病、尼曼-匹克病 C 型、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、Leber 遗传性视神经病变、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。
癌症
食管鳞状细胞癌
Oesophageal squamous cell carcinoma2021–2025 年中国大陆作者发表的 2,923 篇食管鳞状细胞癌 PubMed 英文论文中,这家医院牵头了 3 篇,占 0.1%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 18 家医院列在食管鳞状细胞癌下全国有 191 家医院列在食管鳞状细胞癌下
截至 2026年11月8日,ClinicalTrials.gov 上没有列出这家医院的食管鳞状细胞癌开放试验。
这些数字背后的记录
牵头的论文3
- FOXA3: A Novel Tumor Suppressor in Esophageal Squamous Cell Carcinoma.
- Potential value of CT-based comprehensive nomogram in predicting occult lymph node metastasis of esophageal squamous cell paralaryngeal nerves: a two-center study.
- Transcervical inflatable mediastinoscopic esophagectomy versus thoracoscopic esophagectomy for local early- and intermediate-stage esophageal squamous cell carcinoma: A propensity score-matched analysis.
PubMed 以外找到的论文(未计入)10
- Additional file 2 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 3 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 4 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 5 of PES1 reduces CD8+ T cell infiltration and immunotherapy sensitivity via interrupting ILF3-IL15 complex in esophageal squamous cell carcinoma
- Additional file 1 of OTUB2 Regulates YAP1/TAZ to Promotes the Progression of Esophageal Squamous Cell Carcinoma
- Additional file 1 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 2 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 2 of Serum proteomics unveil characteristic protein diagnostic biomarkers and signaling pathways in patients with esophageal squamous cell carcinoma
- Additional file 4 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
- Additional file 5 of Oxidative stress genes in patients with esophageal squamous cell carcinoma: construction of a novel prognostic signature and characterization of tumor microenvironment infiltration
癌症
肝细胞癌
Hepatocellular carcinoma2021–2025 年中国大陆作者发表的 14,765 篇肝细胞癌 PubMed 英文论文中,这家医院牵头了 15 篇,占 0.1%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在肝细胞癌下全国有 192 家医院列在肝细胞癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
- 分期
- 早期I期
- 开始
- 2024-10
- 登记号
- NCT06418659
年龄 18 岁 至 未注明(登记的条件)
牵头:海军军医大学第二附属医院(长征医院)上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文15
- Effectiveness of Nursing Care Intervention Among Patients With Hepatocellular Carcinoma Undergoing Surgery: A Systematic Review and Meta-Analysis.
- DDR1 is a Novel Biomarker and Potential Therapeutic Target for the Combination Treatment of Liver Hepatocellular Carcinoma.
- Tripartite motif 8 promotes the progression of hepatocellular carcinoma via mediating ubiquitination of HNF1α.
- Profiling of aberrant sialylated N-glycans in hepatocellular carcinoma by liquid chromatography mass spectrometry.
- Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway.
- Dichotomous roles of ADAR1 in liver hepatocellular carcinoma and kidney renal cell carcinoma: Unraveling the complex tumor microenvironment and prognostic significance.
- Abrogating K458 acetylation enhances hepatocyte nuclear factor 4α (HNF4α)-induced differentiation therapy for hepatocellular carcinoma.
- Cathepsin V is correlated with the prognosis and tumor microenvironment in liver cancer.
- Letter: Association between aspirin use and risk of hepatocellular carcinoma in patients with chronic hepatitis B.
- Role of miRNA-99a-5p in Modulating the Function of Hepatocellular Carcinoma Cells: Bioinformatics Analysis and In Vitro Assay.
- Influence of Three-Dimensional Visual Reconstruction Technology Combined with Virtual Surgical Planning of CTA Images on Precise Resection of Liver Cancer in Hepatobiliary Surgery.
- Operator radiation dose during trans-hepatic arterial chemoembolization: different patients' positions via transradial or transfemoral access.
- A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
- Imatinib inhibits the malignancy of hepatocellular carcinoma by suppressing autophagy.
- Combination treatment for advanced hepatocellular carcinoma with portal vein tumour thrombus: A case report.
中文论文(未计入)1
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
- A Clinical Trial Evaluating the Safety and Efficacy of Intravenous CD-801 in Treating Advanced HCC Patients
- A Clinical Trial for the Safety and Efficacy of CD-801 in Patients With Advanced Hepatocellular Carcinoma
- T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
癌症
胃癌
Stomach cancer2021–2025 年中国大陆作者发表的 9,782 篇胃癌 PubMed 英文论文中,这家医院牵头了 17 篇,占 0.2%。
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 18 家医院列在胃癌下全国有 218 家医院列在胃癌下
这家医院参与的开放试验 1
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
- 分期
- II期
- 开始
- 2026-07
- 登记号
- NCT07621484
年龄 18 岁 至 75 岁(登记的条件)
牵头:海军军医大学第二附属医院(长征医院)上海
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文17
- Organoid-based single cell sequencing revealed the lineage evolution during docetaxel treatment in gastric cancer.
- Brucea javanica Seed Oil Emulsion and Shengmai Injections Improve Peripheral Microcirculation in Treatment of Gastric Cancer.
- Effect and Mechanism of 6-Gingerol against Precancerous Lesions of Gastric Cancer Based on Network Pharmacology and In Vitro Experiment.
- Decoding the molecular landscape: HER2 and PD-L1 in advanced gastric cancer.
- Anlotinib plus toripalimab as a first-line treatment in patients with advanced gastric cancer and performance status 2: the phase II APICAL-GC trial.
- Tumor- and metastasis-promoting roles of miR-488 inhibition via HULC enhancement and EZH2-mediated p53 repression in gastric cancer.
- PIK3CA somatic mutations as potential biomarker for immunotherapy in elder or TP53 mutated gastric cancer patients.
- Research progress on the immune microenvironment and immunotherapy in gastric cancer.
- Xiaotan Sanjie decoction normalizes tumor permissive microenvironment in gastric cancer (Review).
- Long non-coding RNA ncRuPAR regulates gastric cancer cell proliferation and apoptosis via phosphoinositide 3-kinase/protein kinase B signaling.
- Folate Decorated Multifunctional Biodegradable Nanoparticles for Gastric Carcinoma Active Targeting Theranostics.
- Ziyin Huatan Recipe, a Chinese herbal compound, inhibits migration and invasion of gastric cancer by upregulating RUNX3 expression.
- UBE3C promotes proliferation and inhibits apoptosis by activating the β-catenin signaling via degradation of AXIN1 in gastric cancer.
- Simultaneous laparoscopic subtotal gastrectomy (Billroth II) and total colectomy with ileorectal anastomosis for synchronous gastric and multifocal colon cancer - a video vignette.
- The effects of gastric cancer interstitial fluid on tumors based on traditional Chinese medicine 'phlegm' theory and the investigation on the mechanism through microRNA-21 regulation.
- Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.
- HER2 Splice Site Mutation c.1899-1G>A as the Potential Acquired Resistance to Trastuzumab in a Patient with HER2-Positive Gastric Adenocarcinoma.
它在 ClinicalTrials.gov 上的全部试验(任何状态)6
- HIPEC Priming Followed by Serplulimab Plus SOX/XELOX in Locally Advanced Gastric Cancer
- Anlotinib Plus Toripalimab as First-line Treatment for Advanced Gastric Cancer With ECOG 2 (APICAL-GC)
- EGFR Monoclonal Antibody for Advanced Gastric Cancer
- Study of Faecal Bacteria Detection in Early Screening and Diagnosis of GC
- XELOX for 4 Months Versus 6 Months in Gastric Cancer (LOMAC)
- A Study of the Efficacy and Safety of PerOx Quench on the Prevention of Oxaliplatin Treatment Induced Neuropathy
癌症
脊索瘤
Chordoma2021–2025 年中国大陆作者发表的 105 篇脊索瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 4.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在脊索瘤下全国有 88 家医院列在脊索瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。
这些数字背后的记录
牵头的论文5
- Targeting the tumor immune microenvironment in chordoma: From mechanistic insights to therapeutic breakthroughs.
- Gross Total Resection of the Entire Cervical Spine Tumor: A Technical Note on Surgical Planning and Design of a Novel 3D-Printed Vertebral Prosthesis for Reconstruction from Skull Base to Thoracic Vertebra.
- Ubiquitin-independent pathway regulates the RIT1-MAPK pathway in chordoma progression.
- A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.
- Early Major Complications After Radical Resection of Primary C2-Involved Upper Cervical Chordoma Through the Combined Anterior Retropharyngeal-Posterior Approach: Incidence and Risk Factors.
早期论文(2016–2020 年)8
- Shifting from targeted therapies to personalised treatment in chordoma - Authors' reply.
- Apatinib in patients with advanced chordoma: a single-arm, single-centre, phase 2 study.
- Application of Individualized 3D-Printed Artificial Vertebral Body for Cervicothoracic Reconstruction in a Six-Level Recurrent Chordoma.
- Recurrence or neurological loss? Resection mode selection for patients with large sacral chordoma: an analysis of prognostic factors and quality of life.
- Prognostic significance of pretreatment plasma D-dimer levels in patients with spinal chordoma: a retrospective cohort study.
- Surgical Consideration for Adolescents and Young Adults With Cervical Chordoma.
- Epidemiological characteristics of primary spinal osseous tumors in Eastern China.
- Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures.
癌症
骨肉瘤
Osteosarcoma2021–2025 年中国大陆作者发表的 2,257 篇骨肉瘤 PubMed 英文论文中,这家医院牵头了 16 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 60 家医院列在骨肉瘤下全国有 742 家医院列在骨肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的骨肉瘤开放试验。
这些数字背后的记录
这些论文过半是实验室或动物研究。
牵头的论文16
- Lactate Activates the HCAR1/β-Arrestin2/PP2A Signaling Axis to Mediate STAT1/2 Dephosphorylation and Drive Osteosarcoma Progression.
- Bone-Targeted Fluoropeptide Nanoparticle Inhibits NF-κB Signaling to Treat Osteosarcoma and Tumor-Induced Bone Destruction.
- Decoding Osteosarcoma's Lactylation Gene Expression: Insights Into Prognosis, Immune Dynamics, and Treatment.
- Targeting AKT as a promising strategy for SOX2-positive, chemoresistant osteosarcoma.
- The malignant dialogue between cancer-associated fibroblasts and osteosarcoma cells: microenvironment-mediated drug resistance and therapeutic targets.
- IL-11-Engineered Macrophage Membrane-Coated Reactive Oxygen Species-Responsive Nanoparticles for Targeted Delivery of Doxorubicin to Osteosarcoma.
- KDELR1 regulates chondrosarcoma drug resistance and malignant behavior through Intergrin-Hippo-YAP1 axis.
- New insights into the mechanisms of the immune microenvironment and immunotherapy in osteosarcoma.
- Small Nuclear Ribonucleoprotein Polypeptides B and B1 Promote Osteosarcoma Progression via Activating the Ataxia-Telangiectasia Mutated Signaling Pathway through Ribonucleotide Reductase Subunit M2.
- Deubiquitinase USP13 regulates glycolytic reprogramming and progression in osteosarcoma by stabilizing METTL3/m6A/ATG5 axis.
- BARX1 promotes osteosarcoma cell proliferation and invasion by regulating HSPA6 expression.
- Prognostic factors of sarcomas occurring in bone and joint: A SEER based study.
- Study on the effect of artificial joint replacement for osteosarcoma.
- AMTB, a TRPM8 antagonist, suppresses growth and metastasis of osteosarcoma through repressing the TGFβ signaling pathway.
- TRIM22 inhibits osteosarcoma progression through destabilizing NRF2 and thus activation of ROS/AMPK/mTOR/autophagy signaling.
- Identifying the Risk Factors and Estimating the Prognosis in Patients with Pelvis and Spine Ewing Sarcoma: A Population-Based Study.
早期论文(2016–2020 年)25
- Secondary aneurysmal bone cyst of the spine: Clinicopathological features, surgical modalities and outcomes.
- The CD24+ cell subset promotes invasion and metastasis in human osteosarcoma.
- Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma.
- Long intergenic non-coding RNA 511 correlates with improved prognosis, and hinders osteosarcoma progression both in vitro and in vivo.
- Hypoxia-Inducible Factor 1A Upregulates HMGN5 by Increasing the Expression of GATA1 and Plays a Role in Osteosarcoma Metastasis.
- The m6A methyltransferase METTL3 promotes osteosarcoma progression by regulating the m6A level of LEF1.
- MicroRNA-221 promotes cisplatin resistance in osteosarcoma cells by targeting PPP2R2A.
- EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma.
- GREM1 overexpression inhibits proliferation, migration and angiogenesis of osteosarcoma.
- Dual targeting curcumin loaded alendronate-hyaluronan- octadecanoic acid micelles for improving osteosarcoma therapy.
- Prognostic Factors for Patients With Undifferentiated High Grade Pleomorphic Sarcoma of the Spine.
- Establishment of a Nomogram-Based Model for Predicting the Prognostic Value of Inflammatory Biomarkers and Preoperative D-Dimer Level in Spinal Ewing's Sarcoma Family Tumors: A Retrospective Study of 83 Patients.
- Histone methyltransferase SETD2 regulates osteosarcoma cell growth and chemosensitivity by suppressing Wnt/β-catenin signaling.
- Heat shock transcription factor 1 promotes the proliferation, migration and invasion of osteosarcoma cells.
- A support vector machine classifier for the prediction of osteosarcoma metastasis with high accuracy.
- Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.
- Factors affecting survival outcomes of patients with non-metastatic Ewing's sarcoma family tumors in the spine: a retrospective analysis of 63 patients in a single center.
- MicroRNA-140-5p regulates osteosarcoma chemoresistance by targeting HMGN5 and autophagy.
- Parthenolide Induces Reactive Oxygen Species-Mediated Autophagic Cell Death in Human Osteosarcoma Cells.
- Promotion of tumour proliferation, migration and invasion by miR-92b in targeting RECK in osteosarcoma.
- TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma.
- Effects of RNA interference-mediated knockdown of livin and survivin using monomethoxypolyethylene glycol-chitosan nanoparticles in MG-63 osteosarcoma cells.
- miR-146b-5p promotes invasion and metastasis contributing to chemoresistance in osteosarcoma by targeting zinc and ring finger 3.
- The predictive potential and oncogenic effects of HOXC8 expression on osteosarcoma.
- P50-associated COX-2 extragenic RNA (PACER) overexpression promotes proliferation and metastasis of osteosarcoma cells by activating COX-2 gene.
癌症
胃肠道间质瘤
Gastrointestinal stromal tumour2021–2025 年中国大陆作者发表的 523 篇胃肠道间质瘤 PubMed 英文论文中,这家医院牵头了 4 篇,占 0.8%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 21 家医院列在胃肠道间质瘤下全国有 261 家医院列在胃肠道间质瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的胃肠道间质瘤开放试验。
这些数字背后的记录
牵头的论文4
- ASO Author Reflections: Simultaneous Robotic Surgery for Rectal Gastrointestinal Stromal Tumor and Prostatic Cancer.
- Simultaneous Robotic Sphincter-Preserving Rectal Resection and Prostatectomy for Rectal Gastrointestinal Stromal Tumor and Prostatic Cancer.
- Clinical features and surgical treatments of rare gastrointestinal stromal tumor spinal metastases.
- Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors.
早期论文(2016–2020 年)4
- Open transanal resection of low rectal stromal tumor following neoadjuvant therapy of imatinib mesylate: Report of 11 cases and review of literature.
- Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
- Value of contrast-enhanced harmonic endoscopic ultrasonography in differentiating between gastrointestinal stromal tumors: A meta-analysis.
- Mutational inactivation of mTORC1 repressor gene DEPDC5 in human gastrointestinal stromal tumors.
癌症
神经母细胞瘤
Neuroblastoma2021–2025 年没有牵头神经母细胞瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在神经母细胞瘤下全国有 352 家医院列在神经母细胞瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的神经母细胞瘤开放试验。
癌症
尤文肉瘤
Ewing sarcoma2021–2025 年中国大陆作者发表的 163 篇尤文肉瘤 PubMed 英文论文中,这家医院牵头了 2 篇,占 1.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在尤文肉瘤下全国有 139 家医院列在尤文肉瘤下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的尤文肉瘤开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)3
- EWS-FLI1-mediated tenascin-C expression promotes tumour progression by targeting MALAT1 through integrin α5β1-mediated YAP activation in Ewing sarcoma.
- Establishment of a Nomogram-Based Model for Predicting the Prognostic Value of Inflammatory Biomarkers and Preoperative D-Dimer Level in Spinal Ewing's Sarcoma Family Tumors: A Retrospective Study of 83 Patients.
- Factors affecting survival outcomes of patients with non-metastatic Ewing's sarcoma family tumors in the spine: a retrospective analysis of 63 patients in a single center.
血液疾病
多发性骨髓瘤
Multiple myeloma2021–2025 年中国大陆作者发表的 1,676 篇多发性骨髓瘤 PubMed 英文论文中,这家医院牵头了 26 篇,占 1.6%。
上海有 16 家医院列在多发性骨髓瘤下全国有 178 家医院列在多发性骨髓瘤下
这家医院参与的开放试验 6
依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。
- 正在招募Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
- 分期
- 早期I期
- 开始
- 2024-06
- 登记号
- NCT06407947
年龄 18 岁 至 未注明(登记的条件)
牵头:海军军医大学第二附属医院(长征医院)上海
- 正在招募a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
- 分期
- 早期I期
- 开始
- 2024-12
- 登记号
- NCT06718270
年龄 18 岁 至 未注明(登记的条件)
牵头:海军军医大学第二附属医院(长征医院)上海
- 正在招募KPD Consolidation After ASCT in NDMM Patients
- 分期
- II/III期
- 开始
- 2025-03
- 登记号
- NCT06879379
年龄 18 岁 至 未注明(登记的条件)
牵头:北京大学人民医院;另有 1 家列出的医院为研究中心上海、北京
- 正在招募To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
- 分期
- 早期I期
- 开始
- 2023-07
- 登记号
- NCT06045091
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 1 家列出的医院为研究中心上海
- 正在招募A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- 分期
- IV期
- 开始
- 2022-03
- 登记号
- NCT05201781
年龄 18 岁 至 未注明(登记的条件)
牵头方不是列出的医院;另有 10 家列出的医院为研究中心上海、北京、南京、广州、成都、杭州、福州、西安
- 正在招募Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
- 分期
- II期
- 开始
- 2022-07
- 登记号
- NCT05594797
年龄 18 岁 至 75 岁(登记的条件)
牵头方不是列出的医院;另有 2 家列出的医院为研究中心上海、温州
排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。
这些数字背后的记录
牵头的论文26
- Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTAN
- Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study.
- Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.
- Efficacy, safety, and pharmacokinetics of teclistamab in Chinese patients with relapsed/refractory multiple myeloma from the China cohort of MajesTEC-1.
- DEK facilitates bortezomib resistance of multiple myeloma by modulating ferroptosis.
- Prognostic significance of hematological parameters and albumin in BCMA-targeted CAR-T therapy for multiple myeloma.
- Extracellular Ubiquitin Drives M2 Macrophage Polarization in Multiple Myeloma Through JAK1/STAT3-mediated Transcriptional Activation of CXCR4.
- CALR regulates the proliferation and drug sensitivity of multiple myeloma cells through the BCL2 signaling pathway.
- GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.
- Interference with PLA2G16 promotes cell cycle arrest and apoptosis and inhibits the reprogramming of glucose metabolism in multiple myeloma cells by modulating the Hippo/YAP signaling pathway.
- Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
- A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.
- B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.
- Cell-free DNA chromosome copy number variations predict outcomes in plasma cell myeloma.
- Identification and validation of a cellular senescence-related lncRNA signature for prognostic prediction in patients with multiple myeloma.
- Sensitive quantitative IgD assay increases progression-free survival prediction accuracy in IgD plasma cell myeloma.
- Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
- CAR-T cell therapy targeting B cell maturation antigen is effective for relapsed/refractory multiple myeloma, including cases with poor performance status.
- Efficacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial.
- Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study.
- Single-cell RNA-seq reveals clonal diversity and prognostic genes of relapsed multiple myeloma.
- Pre-existing hypertension is associated with poor progression-free survival in newly diagnosed multiple myeloma patients.
- CircRNAs: novel therapeutic targets in multiple myeloma.
- Identification of an immunogenic DKK1 long peptide for immunotherapy of human multiple myeloma.
- A study of carfilzomib and dexamethasone in patients with relapsed and refractory multiple myeloma in China.
- Clinical features and survival outcomes in IgD myeloma: a study by Asia Myeloma Network (AMN).
中文论文(未计入)6
- [BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review].
- [The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma].
- [Interpretation of diagnosis of multiple myeloma in the guidelines for the diagnosis and management of multiple myeloma in China (2022 revision)].
- [Analysis of clinical characteristics and prognosis of non-secretory multiple myeloma].
- [A case-control study of multiple myeloma patients with central nervous system involvement].
- [The efficacy and safety of daratumumab in relapsed and refractory multiple myeloma].
它在 ClinicalTrials.gov 上的全部试验(任何状态)36
- Study of CT071 Injection in High Risk Newly Diagnosed Multiple Myeloma
- a Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Plasma Cell Leukemia
- Study of CT071 Injection in RRMM or PPCL
- Study of FasT CAR-T GC012F Injection NDMM Patients
- BCMA-targeted LCAR-BCDR Cells in Patients With Relapsed/Refractory Multiple Myeloma
- Study of Dual Targeted CD19/BCMA FASTCART GC012F in Relapsed/ Refractory Multiple Myeloma
- BCMA and CD19 Targeted Fast Dual CART for Chromosomal Abnomalities High-risk BCMA+ Multiple Myeloma
- Study of FasT CAR-T GC012F Injection in High Risk TE NDMM Patients
- BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma
- Evaluation of Ultrasensitive Chromosomal Aneuploidy Detection for Detecting Minimal Residual Disease in Multiple Myeloma
- A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma
- Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMM
- A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
- Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
- KPD Consolidation After ASCT in NDMM Patients
- To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL
- Human BCMA Targeted T Cells Injection(BCMA CAR-T)for Subjects With R/R MM
- A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
- To Evaluate the Safety and Efficacy of Human Derived Anti-BCMA CAR-T Injection for Subjects with R/R MM
- A Study of Daratumumab
- A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma
- A Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Human BCMA Targeted T Cells Injection Therapy for BCMA-positive Relapsed/Refractory Multiple Myeloma
- Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT)
- TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma
- TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma
- A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
- Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
- A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma
- Ixazomib Rollover Study
- A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT)
- Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma
- Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma
血液疾病
血栓性血小板减少性紫癜
Thrombotic thrombocytopenic purpura2021–2025 年中国大陆作者发表的 64 篇血栓性血小板减少性紫癜 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.6%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 2 家医院列在血栓性血小板减少性紫癜下全国有 59 家医院列在血栓性血小板减少性紫癜下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的血栓性血小板减少性紫癜开放试验。
其他疾病
抗 NMDA 受体脑炎
Anti-NMDA receptor encephalitis2021–2025 年中国大陆作者发表的 264 篇抗 NMDA 受体脑炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在抗 NMDA 受体脑炎下全国有 126 家医院列在抗 NMDA 受体脑炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的抗 NMDA 受体脑炎开放试验。
其他疾病
特发性肺纤维化
Idiopathic pulmonary fibrosis2021–2025 年中国大陆作者发表的 989 篇特发性肺纤维化 PubMed 英文论文中,这家医院牵头了 2 篇,占 0.2%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 34 家医院列在特发性肺纤维化下全国有 333 家医院列在特发性肺纤维化下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的特发性肺纤维化开放试验。
这些数字背后的记录
牵头的论文2
其他疾病
肌萎缩侧索硬化症
Amyotrophic lateral sclerosis2021–2025 年没有牵头肌萎缩侧索硬化症的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。
- 牵头论文
- 0
- 2021–2025 年
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 17 家医院列在肌萎缩侧索硬化症下全国有 194 家医院列在肌萎缩侧索硬化症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的肌萎缩侧索硬化症开放试验。
这些数字背后的记录
早期论文(2016–2020 年)1
其他疾病
白塞病
Behçet disease2021–2025 年中国大陆作者发表的 245 篇白塞病 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.4%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 15 家医院列在白塞病下全国有 149 家医院列在白塞病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。
这些数字背后的记录
其他疾病
IgA 肾病
IgA nephropathy2021–2025 年中国大陆作者发表的 736 篇IgA 肾病 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 26 家医院列在IgA 肾病下全国有 346 家医院列在IgA 肾病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的IgA 肾病开放试验。
这些数字背后的记录
牵头的论文5
- Efficacy and safety of obinutuzumab on progressive IgA nephropathy: a case series.
- Efficacy and safety of TRF-budesonide in IgA nephropathy treatment: a meta-analysis.
- Identification of key necroptosis-related genes and immune landscape in patients with immunoglobulin A nephropathy.
- Molecular characterization of m6A RNA methylation regulators with features of immune dysregulation in IgA nephropathy.
- Coexistence of anti-glomerular basement membrane disease and IgA nephropathy: an illustrative case and comprehensive literature review.
其他疾病
成骨不全症
Osteogenesis imperfecta2021–2025 年中国大陆作者发表的 99 篇成骨不全症 PubMed 英文论文中,这家医院牵头了 2 篇,占 2.0%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 6 家医院列在成骨不全症下全国有 59 家医院列在成骨不全症下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的成骨不全症开放试验。
这些数字背后的记录
牵头的论文2
早期论文(2016–2020 年)3
- Efficacy of Bisphosphonates on Bone Mineral Density and Fracture Rate in Patients With Osteogenesis Imperfecta: A Systematic Review and Meta-analysis.
- Response to Comment on Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
- Strontium Ranelate Reduces the Fracture Incidence in a Growing Mouse Model of Osteogenesis Imperfecta.
其他疾病
原发性胆汁性胆管炎
Primary biliary cholangitis2021–2025 年中国大陆作者发表的 300 篇原发性胆汁性胆管炎 PubMed 英文论文中,这家医院牵头了 1 篇,占 0.3%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 17 家医院列在原发性胆汁性胆管炎下全国有 173 家医院列在原发性胆汁性胆管炎下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的原发性胆汁性胆管炎开放试验。
这些数字背后的记录
早期论文(2016–2020 年)3
- New-onset primary biliary cholangitis in anti-mitochondrial antibody-positive patients may be underestimated without liver biopsy.
- Implication of increased serum stromal cell-derived factor-1 for primary biliary cholangitis.
- Decreased expression of TIPE2 contributes to the hyperreactivity of monocyte to Toll-like receptor ligands in primary biliary cirrhosis.
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
其他疾病
家族性腺瘤性息肉病
Familial adenomatous polyposis2021–2025 年中国大陆作者发表的 59 篇家族性腺瘤性息肉病 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.7%。
- 牵头试验
- 0
- 任何状态,ClinicalTrials.gov
- 牵头的开放试验
- 0
- 正在或即将招募
- 作为研究中心的开放试验
- 0
- 由其他机构牵头
上海有 9 家医院列在家族性腺瘤性息肉病下全国有 76 家医院列在家族性腺瘤性息肉病下
截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的家族性腺瘤性息肉病开放试验。
其他相关研究
联系这家医院
出示给工作人员或司机的院名卡
海军军医大学第二附属医院(长征医院)
Changzheng Hospital
上海
大医院往往有多个院区,出发前请先向医院确认院区。
中英对照的咨询信
填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。
医院通常需要的资料
- 主治医生近期的病情总结或信件
- 病理报告
- 影像检查(CT、MRI、PET)及报告,尽量附影像文件
- 已接受的治疗及时间
- 目前用药
下一步建议
这些数字从哪里来
论文
2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义
试验
ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。
编号与其他名称
ROR
Shanghai Changzheng Hospital; Second Affiliated Hospital of Naval Medical University; Changzheng Hospital of Naval Medicine University; Changzheng Hospital of the Navy Medical University; Zhabei Branch of Changzheng Hospital; Changzheng Hospital of Naval Medical University; Second Military Medical University/Changzheng Hospital; ChangZheng Hospital